Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary Tianyuan Pharmaceutical won the bid for the centralized procurement of traditional Chinese medicine in Guangdong [5] - The company received various drug registration certificates and approvals for its products in 2025 [5][6] - The company completed the redemption of its convertible bonds in August 2025 [6] - The company’s subsidiary Haichang Pharmaceutical obtained market access for several raw materials in South Korea and India [6] Financial Data and Indicators - The report indicates that all board members attended the meeting to review the report [2] - The company’s half-year report was disclosed on August 26, 2025, on designated platforms [8] - The company confirmed the accuracy and completeness of the information disclosed in the report [8]

Core Viewpoint - North Lu Pharmaceutical (300016) reported a strong performance in the first half of 2025, with significant growth in revenue and net profit, driven by stable growth in chemical drugs, traditional Chinese medicine, and raw materials [1][2][3]. Revenue and Profit Growth - The company achieved operating revenue of 584.21 million yuan, a year-on-year increase of 23.27% [1] - Net profit attributable to shareholders reached 29.97 million yuan, up 53.35% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 29.74 million yuan, reflecting a 55.58% increase year-on-year [1] - Both revenue and profit showed growth momentum in the second quarter compared to the first quarter [1] Product Performance - Contrast agents saw a sales revenue of 338.88 million yuan, growing by 21.11% year-on-year [2] - The sales revenue of hypoglycemic products was 68.22 million yuan, with a growth of 2.22% [2] - The chemical drug segment generated a total sales revenue of 407.09 million yuan, an increase of 17.47% year-on-year [2] - Traditional Chinese medicine (TCM) preparations achieved sales revenue of 118.19 million yuan, marking a growth of 32.84% [4] Strategic Developments - The company has expanded its TCM product matrix significantly, now offering 59 varieties, including 21 that are currently marketed [3][10] - The "Nine Flavors Heart-Calming Granules" is recognized as the first pure TCM preparation approved for treating generalized anxiety disorder, establishing the company as a leader in this niche [3] - The company’s raw material drug segment reported sales revenue of 53.40 million yuan, with a year-on-year increase of 45.81% [6] International Market Expansion - The company is actively expanding into overseas markets, achieving overseas revenue of 74.29 million yuan, a growth of 30.41% [8] - The company has received approvals for its contrast agents and iodine contrast raw materials in multiple countries, facilitating further international market access [7] Research and Development - R&D investment reached 39.03 million yuan, a 10.09% increase compared to the previous year [9] - The company has 34 projects in the pipeline, including 16 under review and 18 newly initiated [9] - The company continues to enhance its product pipeline in the contrast agent field, with several raw materials approved for market [9] Financial Management - The company completed the early redemption of its convertible bonds on July 14, 2025, significantly reducing financial pressure [11] - The completion of this redemption is expected to improve the company's capital structure and lower financial costs [11]

Core Viewpoint - North Lu Pharmaceutical (北陆药业) reported strong financial performance for the first half of 2025, with significant growth in revenue and net profit, driven by stable growth in chemical drugs, traditional Chinese medicine, and raw materials [1][2][3][4][5][6]. Financial Performance - The company achieved operating revenue of 584.21 million yuan, a year-on-year increase of 23.27% [1] - Net profit attributable to shareholders reached 29.97 million yuan, up 53.35% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 29.74 million yuan, reflecting a 55.58% increase [1] - Revenue and profit continued to grow in the second quarter compared to the first quarter [1] Product Performance - Contrast agents sales reached 338.88 million yuan, growing by 21.11% [2] - Blood sugar products generated sales of 68.22 million yuan, with a growth of 2.22% [2] - The chemical drug segment achieved sales of 407.09 million yuan, an increase of 17.47% [2] - Traditional Chinese medicine revenue grew by 32.84%, totaling 118.19 million yuan [4] - Raw materials revenue surged by 45.81%, amounting to 53.40 million yuan [6] Strategic Developments - The company has successfully integrated its traditional Chinese medicine segment, expanding its product matrix to 59 varieties, with 21 currently in production and sales [3][10] - The company’s unique products, such as Jiuwu Zhenxin Granules, have established a strong market presence in the anti-anxiety category [3][10] - The company is actively expanding its overseas market presence, achieving overseas revenue of 74.29 million yuan, a growth of 30.41% [8][7] Research and Development - R&D investment reached 39.03 million yuan, a 10.09% increase year-on-year [9] - The company has 34 projects in the pipeline, including 16 under review and 18 newly initiated [9] - The company continues to enhance its product offerings in the contrast agent field, with several raw materials approved for market entry [9] Financial Structure - The company completed the redemption and delisting of its convertible bonds, significantly reducing financial pressure [11]

格隆汇8月25日丨北陆药业(300016.SZ)公布2025年半年度报告，上半年公司实现营业收入5.84亿元，同 比增长23.27%；归属于上市公司股东的净利润2996.69万元，同比增长53.35%；归属于上市公司股东的 扣除非经常性损益的净利润2973.76万元，同比增长55.58%；基本每股收益0.06元。 ...

法定代表人：王旭 主管会计工作负责人：曾妮 会计机构负责人：曾妮 北京北陆药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 1 单位：万元 非经营性资金占用 资金占用方名称 占用方与 上市公司 的关联关 系 上市公司核 算的会计科 目 2025 年期 初占用资 金余额 2025 年半 年度占用 累计发生 金额（不含 利息） 2025 年半 年度占用 资金的利 息(如有) 2025 年半 年度偿还 累计发生 金额 2025 年 6 月 30 日 期末占用 资金余额 占用形成 原因 占用性质 控股股东、实际控制人及其 附属企业 小计 前控股股东、实际控制人及 其附属企业 小计 其他关联方及附属企业 小计 总计 其他关联资金往来 资金往来方名称 往来方与 上市公司 的关联关 系 上市公司核 算的会计科 目 2025 年期 初占用资 金余额 2025 年半 年度占用 累计发生 金额（不含 利息） 2025 年半 年度占用 资金的利 息(如有) 2025 年半 年度偿还 累计发生 金额 2025 年 6 月 30 日 期末占用 资金余额 往来形成 原因 往来性质 控股股东、实际控制人及其 ...

北京北陆药业股份有限公司 董事会 二○二五年八月二十六日 1 北京北陆药业股份有限公司 2025年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司《2025 年半年度报告》及其摘要已于 2025 年 8 月 26 日在中国证监会指定的创业板信息披露网站上披露，《2025 年半年度 报告摘要》同时刊登在公司指定信息披露报刊：《中国证券报》、《证券时 报》及《上海证券报》，请投资者注意查阅。 特此公告。 股票代码：300016 股票简称：北陆药业 公告编号：2025-092 ...

2025年半年度募集资金存放与使用情况的专项报告 根据《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管 指引第 2 号-创业板上市公司规范运作》有关规定，现将本公司 2025 年半年度募 集资金存放与使用情况说明如下： 股票代码：300016 股票简称：北陆药业 公告编号：2025-095 北京北陆药业股份有限公司 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意北京北陆药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2020〕2810 号）核准，公司 向社会公开发行面值不超过人民币 500,000,000.00 元的可转换公司债券。根据《北 京北陆药业股份有限公司向不特定对象发行可转换公司债券发行公告》，公司债 券发行面值 50,000 万元，每张面值为人民币 100 元，共计 500 万张，发行价格为 100 元/张。扣除与本次发行有关的费用 10,775,471.70 元（不含增值税）后，实际 募集资金净额为 489,224,528.30 元。 截至 2020 年 12 月 11 日，扣除不含税承销费用（本次合计不含税保 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-096 北京北陆药业股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第三次 会议于2025年8月22日下午以现场及通讯相结合的方式召开，会议通知以邮件 方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参加 表决董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的有 关规定。会议由董事长王旭先生主持，与会董事以记名投票方式审议通过了 以下议案： 一、《2025年半年度报告》及其摘要 《2025 年半年度报告》及其摘要详见巨潮资讯网（www.cninfo.com.cn） 等中国证监会指定信息披露网站。《2025 年半年度报告披露提示性公告》及 《2025 年半年度报告摘要》同时刊登在公司指定信息披露报刊：《中国证券报》、 《证券时报》及《上海证券报》。 本报告已经公司第九届董事会审计委员会第二次会议审议通过。 表决结果：9 票同意，0 票反对，0 票弃权。 二、2025 年 ...

公告编号：2025-093 北京北陆药业股份有限公司 BEIJING BEILU PHARMACEUTICAL CO.,LTD. 2025 年半年度报告 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 股票代码：300016 股票简称：北陆药业 披露日期：2025.08.26 1 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责 任。 公司负责人王旭、主管会计工作负责人及会计机构负责人(会计主管人员) 曾妮声明：保证本半年度报告中财务报告的真实、准确、完整。 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及 应对措施，请查阅"第三节 管理层讨论与分析"之"十、公司面临的风险和 应对措施"。敬请投资者予以关注，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股 ...

金融界消息 截至2025年8月25日收盘，北陆药业（300016）报收于10.3元，上涨3.21%，换手率8.87%， 成交量49.87万手，成交金额5.06亿元。 天眼查商业履历信息显示，北京北陆药业股份有限公司，成立于1992年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本49185.5896万人民币，实缴资本3838.8491万人民币。公司法定代表 人为王旭。 通过天眼查大数据分析，北京北陆药业股份有限公司共对外投资了15家企业，参与招投标项目3042次， 知识产权方面有商标信息80条，专利信息14条，此外企业还拥有行政许可113个。 来源：金融界 资金流向方面，今日主力资金净流入4550.55万元，占比成交额8.99%。其中，超大单净流入1003.92万 元、占成交额1.98%，大单净流入3546.62万元、占成交额7.01%，中单净流出流出1295.66万元、占成交 额2.56%，小单净流出3254.89万元、占成交额6.43%。 北陆药业最新一期业绩显示，截至2025一季报，公司营业总收入2.83亿元、同比增长36.23%，归属净利 润1453.85万元，同比增长26.13%，扣非 ...